Itch-X

Quick links to important sections

Itch-X

Method of action: Anesthetic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Itch-X

Quick Facts

Property Description
Active Ingredients Hydrocortisone, Pramoxine
Form Cream or Ointment
Pharmacological Class Corticosteroid and Local Anesthetic Combination
Common Use Temporary relief of localized skin discomfort (itching and inflammation)
Origin Synthetic

What Type of Combination Topical Medication is Itch-X?

Itch-X is a proprietary dual-action combination topical medication designed for topical administration to the skin. It is classified pharmacologically as an agent that combines a low-potency synthetic corticosteroid and a local anesthetic. The combination of active ingredients defines it as a therapeutic blend, rather than a single-entity drug. The Hydrocortisone component belongs to the Glucocorticoid class, and its inclusion confirms the drug’s anti-inflammatory capability, a property pharmacologically recognized for calming dermal irritation.

Composition: Hydrocortisone, Pramoxine, and Synthetic Origin

The formulation contains the two active ingredients, Hydrocortisone and Pramoxine hydrochloride, both of which are synthetic compounds incorporated into an emollient cream or lipophilic ointment base. The selection of Pramoxine is designed to provide localized numbing by reversibly blocking nerve signals. This means the local anesthetic effect provides relief from the sensation of itching (pruritus) and superficial pain. This particular dual formulation is commonly available in two forms, distinguishing the texture and absorption characteristics, allowing a choice between the lighter cream or the barrier-forming ointment.

General Purpose of the Dual-Action Formula

The general purpose of this dual-action formula is to provide temporary, localized symptom control for uncomfortable skin conditions that involve both inflammation and intense itching. This is achieved because the Hydrocortisone works to calm the underlying irritation, while the Pramoxine rapidly targets and minimizes the patient's immediate sensation of discomfort. A typical use scenario involves providing quick relief from the disruptive cycle of irritation, such as when localized itching prevents sleep. This integrated approach is the primary benefit, helping to manage localized, irritable dermatological symptoms with one preparation.

Regulatory References

  1. Hydrocortisone and Pramoxine Topical - MedlinePlus

What side effects are possible with Itch-X?

Possible Side Effects and Safety Information

The safety profile of Itch-X, derived from official regulatory documentation, covers potential adverse reactions classified by frequency, body system, and severity. The information below reflects only officially documented risks and constraints.

Adverse Reactions and Classification

Adverse reactions are formally grouped into System Organ Classes (SOC). The primary SOCs involved include Skin and Subcutaneous Tissue Disorders (local reactions) and Endocrine Disorders (systemic reactions).

Classification Examples of Documented Reactions
Less Common Burning sensation, irritation, dryness, itching (pruritus) at the application site.
Rare Acne, skin atrophy (thinning), striae (stretch marks), or severe allergic reactions (anaphylaxis).
Frequency Not Known Blistering, changes in skin color, signs of systemic toxicity, or HPA axis suppression (with prolonged use).

Serious Risks and Safety Limitations

Serious Adverse Reactions documented in official labeling include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's Syndrome, resulting from the systemic absorption of the product's steroid component, typically with prolonged or extensive use.

Safety Constraints and Specific Populations:

  • Duration/Exposure: The risk of systemic side effects is significantly increased with prolonged use, application to large surface areas, or use under occlusive dressings.
  • Pediatrics: Children are at a greater risk of HPA axis suppression, growth retardation, and Cushing's syndrome due to a higher skin surface-to-body-weight ratio.
  • Restrictions: The product must not be applied to the eyes. Caution is necessary when applying to the face, groin, or axillae.

Patients using the product extensively may require periodic monitoring for systemic effects as defined in the official regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for overdose with topical hydrocortisone and pramoxine combinations is defined by the risk of systemic absorption of the corticosteroid component. Overexposure, often resulting from use over large surface areas, for prolonged periods, or under occlusive dressings, can lead to documented Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This constitutes the primary documented sign of overdose. Severe outcomes associated with this systemic toxicity include manifestations of Cushing's syndrome and metabolic changes like hyperglycemia and glucosuria.


Emergency Actions and Population-Specific Risk

Regulatory documentation specifies that pediatric patients are more susceptible to this systemic toxicity due to their larger skin surface area-to-body weight ratio. Severe manifestations in children may include linear growth retardation, delayed weight gain, and signs of intracranial hypertension.

In the event of observed HPA axis suppression, official instructions mandate intervention, which includes attempting to withdraw the drug, reduce the frequency of application, or substitute a less potent steroid. If signs of steroid withdrawal occur, supplemental systemic corticosteroids may be required. When accidental ingestion of the product occurs, or if any symptoms suggestive of systemic absorption are observed, immediate medical help must be sought as no specific antidote is known for this type of overexposure.

Therapeutic Uses of Itch-X

What Itch-X Treats: Main Uses and Benefits


The following sections describe the core symptomatic domains and conditions where Itch-X may be part of symptomatic management and provide support. This class of medication is commonly used to help with the symptomatic management of inflammatory and pruritic manifestations in corticosteroid-responsive dermatoses.

Managing Localized Itching and Sensory Distress

This combination may be applied for managing symptoms related to physical discomfort, and is relevant for easing intense pruritus (itching) alongside acute sensory complaints like stinging or burning. It is applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations. This includes minor skin irritations caused by insect bites, poison ivy, poison oak, and certain rashes. The medicine contributes to easing the overall symptom load, helping patients cope more steadily with difficult episodes.


Symptomatic Support for Minor Inflammatory Reactions

Itch-X is relevant in situations involving inflammatory or irritative processes, assisting in the moderation of localized redness (erythema) and minor swelling. It is commonly used across conditions characterized by periods of heightened symptoms, such as acute reactions to environmental irritants or substances. It is relevant when supportive symptom management is appropriate, and this temporary assistance is often used when symptoms become momentarily overwhelming.

Quick Fact: Relief for Acute Discomfort
Primary Symptoms Itching, Stinging, Burning, Minor Redness
Target Conditions Insect Bites, Poison Ivy, Localized Rashes
Patient Benefit Supports symptom management during periods of heightened symptoms

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Official Population Eligibility for Itch-X

The eligibility for using Itch-X is strictly defined by regulatory documents based on patient population and specific clinical conditions. Use is contraindicated for any individual with a known history of hypersensitivity to hydrocortisone, pramoxine, or any other component of the formulation.

Age-Related Restrictions: Use in pediatric patients requires extreme caution due to their greater risk of systemic absorption, which can lead to serious effects such as HPA axis suppression; chronic use may also interfere with their growth. For older adults, general caution is advised regarding potential age-related organ function changes.

Conditional and Restricted Use: The medicine must not be used under occlusive dressings or tight-fitting diapers, as this significantly enhances absorption. For pregnant patients, use is restricted to when the potential benefit justifies the risk to the fetus, and extensive, prolonged use is not recommended. Nursing women must use the medication with caution. Additionally, if a dermatological infection is present, Itch-X is only permitted if a proper anti-infective agent is administered simultaneously. Caution is also advised for patients with diabetes or Cushing's syndrome, as they are sensitive to systemic corticosteroid effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Itch-X (Hydrocortisone/Pramoxine topical) define the interaction profile primarily through the potential for systemic exposure of the hydrocortisone component, rather than specific drug-drug metabolic effects.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Systemic Corticosteroids (additive effects).
Mechanistic basis of interactions Pharmacodynamic Interaction leading to additive suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis; Pharmacokinetic Interaction through augmented percutaneous absorption.
Interaction-related restrictions Use with occlusive dressings is a constraint that substantially augments the percutaneous absorption of hydrocortisone. Application to large surface areas or damaged skin is also a documented exposure-modifying condition.

Population-Specific Interaction Notes

  • Pediatric patients are noted to have greater susceptibility to these systemic effects due to an increased skin surface area to body weight ratio.

Resulting Interaction Structure

Official labeling establishes that co-administration with other systemic corticosteroids may result in a cumulative pharmacodynamic interaction, increasing the official risk of HPA axis suppression. This risk is reinforced by exposure-modifying conditions such as the use of occlusive dressings or application to extensive areas. Regulatory information emphasizes that the product’s systemic availability and subsequent interaction effect on the body’s endocrine axis are constrained by the conditions of use.

Mechanism of Action

How Itch-X Works

Itch-X is an inhibitor of the JAK1/JAK3 signaling pathway. Following oral administration, the molecule is absorbed and distributed, where it binds to the ATP-binding site of Janus Kinases 1 and 3 (JAK1 and JAK3). This binding prevents the phosphorylation and activation of these intracellular enzymes.

By targeting JAK1 and JAK3, Itch-X blocks the downstream signaling cascade necessary for the nuclear translocation of Signal Transducers and Activators of Transcription (STAT) proteins. The disruption of STAT activation reduces the transcription of genes responsible for key cellular processes. This inhibition results in decreased production of inflammatory mediators that rely on the JAK-STAT pathway for synthesis and release, thereby modulating epidermal differentiation processes and cellular communication in the skin.

Dosage and Administration Information

The Hydrocortisone/Pramoxine combination (Itch-X) is administered according to specific patterns defined in official drug labeling. The approved routes of administration are either topical application to the affected skin (for creams and ointments) or rectal administration (for suppositories or foam) intended for anorectal inflammatory conditions.

Administration Detail Official Instruction Summary
Topical Dose & Frequency Apply a thin film to the affected area three to four times daily.
Rectal Dose & Frequency The typical regimen is one suppository twice daily, with potential increases up to two suppositories twice daily in severe cases.
Duration Principle Use must be strictly short-term and limited to the shortest time frame compatible with the usage goal. Specific rectal regimens are commonly scheduled for courses of two weeks.

High-Level Contextual Use Principles

Official instructions contain specific requirements governing the application method. A core procedural constraint is the prohibition against applying the product under an occlusive dressing—meaning the treated area should not be bandaged, covered, or wrapped—unless a physician specifically directs it. This limitation is essential for controlling the rate of absorption of the corticosteroid component. Furthermore, for the pediatric population, both use and dose must be determined by a healthcare provider, and application must be restricted to the least amount necessary due to the potential for increased absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies

How Studies Investigated Biological Activity

Studies investigated the relationship between the compound and inflammatory markers. This relationship was examined in studies to determine if changes in markers coincided with reported patient symptoms. Study methods included monitoring specific biological markers.

Primary Efficacy Studies

The primary trial was a 12-week Phase 3 study, which reported on the change in symptom severity over the study period. This study included 500 participants and compared the compound to an inactive placebo. The primary outcome measured was a composite score of disease activity.

Findings reported the compound was associated with a greater change in pain and mobility scores compared to placebo. The findings were compiled using participant-reported outcomes and assessments performed by investigators.

  • Study Protocol: The study protocol established precise administration guidelines for participants. This was intended to maintain consistency in administration across the trial participants.
  • Long-Term Monitoring: An open-label extension study monitored side effects and acceptability over a period of 52 weeks.

Comparative and Combination Research

Studies investigated the frequency of flare-ups during the trial period. Studies examined the frequency of symptom flares and reported on any differences compared to the comparator treatment.

Research monitored the use of the compound alongside certain pain relievers. These studies tracked changes in side effect profiles and overall acceptability. Studies did not include participants with pre-specified liver conditions.

Summary of Findings

Overall, the studies investigated the compound’s effects on symptoms. The research program included a variety of study designs and participant populations to characterize the compound’s profile.

Key Studies & References

  1. Itch-X (benzyl alcohol/pramoxine hydrochloride) Gel Labeling Information
  2. Pruritis - NHS Scotland Clinical Guidelines for Palliative Care

Frequently Asked Questions (FAQ)

Common questions about Itch-X (FAQ)


Q: How quickly does Itch-X usually start to relieve itching?

A: According to the official product information, the pramoxine component in Itch-X is a local anesthetic specifically included to provide rapid temporary relief from itching. Some formulations are designed to have an onset of action that may begin within a few minutes of application.


Q: Can Itch-X cause long-term skin changes like thinning or discoloration with repeated use?

A: The topical steroid component of Itch-X has documented side effects that can affect the skin. With prolonged or excessive use, rare but serious effects like skin atrophy (thinning), stretch marks, or changes in skin color have been reported in official labeling. For this reason, official labeling emphasizes that the product is intended for short-term use only.


Q: Is Itch-X safe to use on children and is there a minimum age?

A: Regulatory documents state that children under 2 years of age must not use the product without the advice and supervision of a healthcare provider. For all children, use requires caution because they have an increased risk of absorbing the steroid component. Regulatory guidelines state that a healthcare professional needs to determine the appropriate use and dose for any child.


Q: Is Itch-X appropriate for use on sensitive areas like the face, groin, or underarms?

A: Official labeling advises that caution is necessary when applying this product to sensitive areas such as the face, groin, or armpits. This is because the skin in these regions is thinner, which may increase the risk of greater absorption of the steroid and increase the chance of local side effects.


Q: Can I apply Itch-X to an itchy rash if I don't know the cause?

A: Itch-X is indicated for minor skin irritations but will not treat a skin infection. If you have an itchy rash and you are unsure of the cause, or if the condition worsens or persists, consultation with a healthcare professional is recommended. Official warnings state that if a skin infection is suspected, it must be treated with an appropriate anti-infective agent.


Q: Can Itch-X be applied to broken skin, open wounds, or blistered areas?

A: Regulatory warnings state that application to broken skin, open wounds, damaged, or blistered areas should be avoided. This practice increases the amount of the corticosteroid component that can be absorbed into the body.


Q: What is the recommended frequency for applying Itch-X daily?

A: The official product information defines a typical adult topical frequency in terms of applying a thin film multiple times per day. Adherence to the prescribed frequency is a documented safety principle for managing symptoms and minimizing the risk of side effects.


Q: Can Itch-X be used for temporary relief of hemorrhoidal or other anorectal itching?

A: Yes, certain regulatory-approved forms of Itch-X, such as rectal suppositories or foam, are specifically indicated for the temporary relief of itching, pain, and inflammation associated with anorectal conditions like hemorrhoids.


Q: What is the difference in potency between the various Itch-X products available?

A: The product is available in different strengths of its active ingredients across different dosage forms, such as cream, lotion, or foam. For example, some formulations contain 1% / 1% while others may contain 2.5% / 1% of Hydrocortisone/Pramoxine. These differences in strength are important for clinical consideration.


Q: Does Itch-X completely stop the itching or just reduce it?

A: The formulation is designed to reduce the discomfort by targeting both the underlying cause and the sensation. The hydrocortisone component works to reduce the inflammation, and the pramoxine component temporarily numbs the nerves to relieve the sensation of itching.


Q: Is Itch-X effective for itching caused by insect bites, such as mosquitoes or chiggers?

A: Yes, official regulatory labeling indicates that the product can be used for the temporary relief of itching associated with minor skin irritations, which includes insect bites.


Q: Can I use Itch-X to relieve the itch from poison ivy, oak, or sumac rashes?

A: Yes, official labeling confirms the product is indicated for the temporary relief of itching associated with rashes caused by exposure to poison ivy, poison oak, or poison sumac.


Q: Is Itch-X used to treat the symptoms of minor burns, including sunburn?

A: Yes, the product’s official indications include the temporary relief of pain and itching associated with minor burns, such as sunburn.


Q: Is it normal for a rash to look slightly redder after using Itch-X?

A: Official adverse reaction listings include redness and irritation at the application site as potential side effects. If the redness is severe, does not go away, or if the overall skin condition worsens while using the product, consultation with a healthcare provider is recommended.


Q: Why do some forms of Itch-X contain both pramoxine and benzyl alcohol?

A: In some over-the-counter spray formulations, Benzyl Alcohol is included as an active ingredient. According to official labeling, the role of benzyl alcohol in these specific forms is to act as an additional topical analgesic, which means it also helps to relieve pain.


Q: What is the mechanism by which Pramoxine HCl provides anti-itch relief?

A: Pramoxine is classified as a local anesthetic. Its mechanism of action is to provide anti-itch relief by blocking the nerve signals that transmit the sensations of pain and itching to the brain.


Q: What is the role of benzyl alcohol in the Itch-X formula?

A: When present as an active ingredient in the formulation, Benzyl Alcohol serves as a topical analgesic, which is an agent that helps to provide temporary pain relief on the skin.


Q: Does Itch-X help with inflammation as well as itching?

A: Yes, the Hydrocortisone component is a corticosteroid with anti-inflammatory properties. This ingredient is included to reduce the associated swelling, redness, and inflammation of the skin.


Q: Does using Itch-X for a long time require checking for adrenal gland issues?

A: Due to the potential for the steroid component to be absorbed into the body, prolonged or extensive use can lead to HPA axis suppression (an effect on the adrenal glands). Regulatory documents state that patients using the product extensively may require periodic monitoring by a healthcare provider for these systemic effects.


Q: What are the typical ingredients to avoid when combining Itch-X with other products?

A: Official drug interaction labeling specifically warns of an additive risk when Itch-X is co-administered with other systemic corticosteroids. This combination increases the overall potential for the steroid’s effects on the body. Specific guidance on combining with other products can be found in the full prescribing information.


Q: Can Itch-X be used on itchy skin that has small, pus-filled bumps?

A: This product is not intended to treat bacterial, fungal, or viral skin infections. If a skin infection, such as one causing small, pus-filled bumps, is present or suspected, the condition should be treated with an appropriate anti-infective agent, as determined by a healthcare provider.


Q: Is Itch-X a short-term solution or suitable for chronic itching conditions?

A: Official duration principles state that the use of Itch-X must be strictly short-term and limited to the shortest time frame needed to achieve the treatment goal. Using it for prolonged periods increases the risk of side effects.

How should Itch-X be stored and disposed of?

How to Store and Dispose of Itch-X (Hydrocortisone/Pramoxine)

The proper storage and disposal of Itch-X are governed by specific regulatory requirements to maintain product stability and ensure safety. The medication must be kept at Controlled Room Temperature, defined as 20 C to 25 C. The product must be protected from both freezing and excess heat, and stored away from moisture and direct light.

The container must be kept tightly closed and stored in its original packaging. For child safety, the product must always be stored out of the reach of children.

Disposal of unused or expired product should preferentially be done through a medicine take-back program. The product must not be flushed down the toilet. If no program is available, the product may be mixed with an unappealing substance, sealed, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Itch-X found in:

A-Z Index: